Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year?
by Zacks Equity Research
Here is how Clover Health Investments, Corp. (CLOV) and Amedisys (AMED) have performed compared to their sector so far this year.
Encompass Health (EHC) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.
Company News for Jul 27, 2023
by Zacks Equity Research
Companies in The News Are: AMED,SNAP,UNP,WFC
Amedisys (AMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amedisys (AMED) Tops Q2 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 28.04% and 2.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Addus HomeCare (ADUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Amedisys (AMED) Q2 Earnings Expected to Decline
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys (AMED) to Advance Value-Based Care With Optum Merger
by Zacks Equity Research
Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.
UnitedHealth Group (UNH) Expands Home Healthcare Business
by Zacks Equity Research
UnitedHealth Group (UNH) boosts home healthcare presence with the acquisition of Amedisys for $3.3 billion
Are Options Traders Betting on a Big Move in Amedisys (AMED) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.
4 Stocks to Hold in a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.
UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health
by Zacks Equity Research
UnitedHealth (UNH) offers to combine its Optum business with Amedisys to expand its reach in the healthcare-at-home market.
Strength Seen in Amedisys (AMED): Can Its 15.4% Jump Turn into More Strength?
by Zacks Equity Research
Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.
Amedisys (AMED) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amedisys (AMED) Q1 Earnings Top Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 16.28% and 0.58%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable
by Zacks Equity Research
For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.
Here's Why You Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.
Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips
by Zacks Equity Research
Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.
Amedisys (AMED) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 12.62% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Amedisys (AMED) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys (AMED) Faces Macro Challenges, Margin Pressure
by Zacks Equity Research
The Contessa Health acquisition seems to be strategically aligned with Amedisys' (AMED) business.
Are Options Traders Betting on a Big Move in Amedisys (AMED) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.
Amedisys (AMED) Q3 Earnings Miss Estimates, Guidance Cut
by Zacks Equity Research
Within Amedisys (AMED) Home Health and Hospice, the reinstatement of sequestration reduces growth in Q3.